Active, not recruitingPhase 2NCT03314181
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
Studying Multiple myeloma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- Dexamethasone(drug)
- Enrollment
- 156 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2031
Study locations (30)
- Univ of Colorado Cancer Center /ID# 167331, Aurora, Colorado, United States
- Moffitt Cancer Center /ID# 169614, Tampa, Florida, United States
- Winship Cancer Institute of Emory University /ID# 165427, Atlanta, Georgia, United States
- The University of Chicago Medical Center /ID# 165429, Chicago, Illinois, United States
- Beth Israel Deaconess Medical Center /ID# 210904, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute /ID# 166886, Boston, Massachusetts, United States
- Hackensack Univ Med Ctr /ID# 225111, Hackensack, New Jersey, United States
- Duplicate_Roswell Park Comprehensive Cancer Center /ID# 169615, Buffalo, New York, United States
- Weill Cornell Medicine/NYP /ID# 167605, New York, New York, United States
- Atrium Health Carolinas Medical Center /ID# 164948, Charlotte, North Carolina, United States
- Duke Cancer Center /ID# 165104, Durham, North Carolina, United States
- Duplicate_Wake Forest Baptist Health /ID# 224447, Winston-Salem, North Carolina, United States
- Oregon Health and Science University /ID# 166822, Portland, Oregon, United States
- University of Washington /ID# 164884, Seattle, Washington, United States
- The Kinghorn Cancer Centre /ID# 165431, Darlinghurst, New South Wales, Australia
- +15 more locations on ClinicalTrials.gov
Collaborators
Janssen Research & Development, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03314181 on ClinicalTrials.govOther trials for Multiple myeloma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07225738A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma PatientsCity of Hope Medical Center
- RECRUITINGPHASE3NCT06980480A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaTakeda
- RECRUITINGPHASE4NCT07094048Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell EngagerCHU de Quebec-Universite Laval
- RECRUITINGPHASE3NCT07222761A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Regeneron Pharmaceuticals
- RECRUITINGNANCT07226934An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic CancersWashington University School of Medicine
- RECRUITINGEARLY PHASE1NCT07294625A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple MyelomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1NCT07179679A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- RECRUITINGPHASE3NCT06514508Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsGuangzhou Gloria Biosciences Co., Ltd.